http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-50792-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J43-006 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J53-00 |
| filingDate | 1997-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b73a520436fc6a1be538c89503f1a04b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_053202dead49ccaa4cc8cdafe673ec8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e55e9c62c5791fe06815749436afcebd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbf9adc926a66b2f4347134e674607c6 |
| publicationDate | 2002-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-50792-C2 |
| titleOfInvention | Translated By Plaj7b- (o-aminoalkyl) ESTRATRIENES AND THEIR PHARMACEUTICAL PREPARATION |
| abstract | The application describes new, substituted 7B - (- aminoalkyl) estratrienes of General formula I in which the side chain SK is a residue of formula, where m means 4, 5 or 6, n means 0, 1 or 2, x means 0, 1 or 2, A represents a hydrogen atom or a C1-C5alkyl group, B and D each represent a hydrogen atom, or A and D together represent an alkylene group - (CH2) p-, where p means 2, 3, 4 or 5, and D represents a hydrogen atom, or A and D both together represent an alkylene group - (CH2) q-, where q means 2, 3 or 4, and B represents a hydrogen atom, and E represents unsubstituted or mo- to n a fluorinated ethyl residue, or a terminal substituent of - (CH2) 3-E, in the side chain is replaced by an optionally substituted aryl or heteroaryl residue linked directly or through a mono-, di- or trimethylene group to a sulfur atom, R3 represents a hydrogen atom, a hydrocarbon residue with the number of carbon atoms up to 8 or a residue of formula R3 - (CO) -, where R3 means a hydrogen atom or a hydrocarbon residue with the number of atoms carbon to 8 or phenyl residue, R11 represents a hydrogen atom, a halogen atom or a nitrooxy group -O- NO2, R14, R15α, R15β, R16α and R16β each means a hydrogen atom, or R14 and R15α represent an additional bond or a methylene bridge, or R15β represents a methyl group, and R15α represents a hydrogen atom, or R15α and R15β each mean a methyl group, or R15β and R16β together represent a methylene bridge, or R16α or R16β represent a halogen atom, or R16α and R16β both together represent a methyl group. methylidene group, and the other of the substituents R14, R15α, R15β, R16α and R16β each means a hydrogen atom, R17 'in - or --position represents a hydrogen atom, C1-C5alkyl, C2-C5alkenyl or C2-C5alkynyl group or trifluoromethyl group and R17 '' represents a hydrogen atom or a residue of formula R17 '' '- C (O) -, where R17' '' means a hydrogen atom or a hydrocarbon residue with the number of carbon atoms up to 8, or if R17 'is in the -position, then R17 'together with R14 represent an ethane bridge, provided that if A and B are both p azo does not mean - (CH2) p- or A and D both together do not mean - (CH2) q-, at least one of the substituents R11, R14, R15α, R15β, R16α and R16β is not hydrogen, and their physiologically acceptable acid- additive salts of organic and inorganic acids. The new compounds are compounds that have exceptionally high antiestrogenic efficacy. By compounds according to the invention are meant, on the one hand, pure antiestrogens or, on the other hand, antiestrogens with partial estrogenic action. Due to this spectrum of their action, new compounds with maximum effect can be used for the manufacture of drugs for tumor therapy and hormone replacement therapy. |
| priorityDate | 1996-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.